William N. Starling Jr. - 30 Jun 2021 Form 4 Insider Report for ASENSUS SURGICAL, INC.

Role
Director
Signature
/s/ Joshua Weingard, as attorney-in-fact for William N. Starling
Issuer symbol
N/A
Transactions as of
30 Jun 2021
Net transactions value
$0
Form type
4
Filing time
02 Jul 2021, 19:13:10 UTC
Next filing
15 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ASXC Common Stock Award $0 +13,846 +51% $0.000000 40,856 01 Jul 2021 Direct F1, F2
holding ASXC Common Stock 18,134 30 Jun 2021 See Footnote F3
holding ASXC Common Stock 22,849 30 Jun 2021 See Footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ASXC Stock Option Award $0 +4,310 $0.000000 4,310 30 Jun 2021 Common Stock 4,310 $3.17 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.
F2 Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2022 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.
F3 Shares of Common Stock held by Synecor, L.L.C. The Reporting Person is the chief executive officer of Synecor, L.L.C. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F4 Shares of Common Stock held by W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990.
F5 Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended June 30, 2021.
F6 The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors.